Management Team

For over 30 years, Mr. Olson has been a serial founder and entrepreneur in a broad range of medical device, diagnostic, biologic and biomaterial companies. Most recently Mr. Olson was the Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. He is accomplished in leading and motivating all levels of management in a variety of company sizes and industries both domestically and internationally. Mr. Olson previously served as CEO, President, and as a member of the Board of Directors for the Company while it was known as “Amedica Corporation.” Mr. Olson played a key role in the Company’s 2014 initial public offering and becoming listed on the NASDAQ Capital Market. Mr. Olson has served in senior executive roles of President, Chief Executive Officer and as a member of the Board Directors.

Dr. Bock has more than 20 years of experience in advanced ceramic research and development. Since joining SINTX 2008, he has participated in and led process and material development efforts for SINTX’s silicon nitride and subsequent discoveries of silicon nitride’s antipathogenic and biologic properties. Prior to joining SINTX, Dr. Bock was a researcher at the University of California at Santa Barbara, where he developed novel slurry systems for use in colloidal processing of advanced ceramic materials.

Dr. Bock is a co-author of more than 20 peer-reviewed technical papers in subject areas of ceramic science and biomaterials science. He served as a symposium organizer for the Surface Properties of Biomaterials Symposium at the annual Materials Science & Technology technical meeting from 2016 through 2019

Dr. Bock holds a B.S. in Materials Science and Engineering from the University of Florida and a Ph.D. in Biomaterials from the Kyoto Institute of Technology.

Mr. Honigblum has over 35 years’ experience as a financier for emerging growth companies. His professional journey started as a stockbroker on Wall Street, where he transitioned into investment banking. Over time, he honed his craft at various investment banking boutiques in New York City before co-founding Creation Capital LLC and Creation Capital Advisors with offices in New York and Austin, Texas. The firm specialized in founding and funding breakthrough healthcare technologies. From 2003 to 2014 Mr. Honigblum was responsible for raising the Company’s private equity funding prior to its IPO in 2014. From 2006 to 2013, Mr. Honigblum was a member of the Board of Directors of Sintx (formerly Amedica Corporation). Mr. Honigblum was also instrumental in providing early-stage capital for Myriad Genetics (symbol MYGN), the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and subsequently acquired by Merck for $620 million. Mr. Honigblum has raised over $500 million for various ventures and has worked in different parts of the world, including London, Italy, Shanghai, China, and Los Angeles. He holds Series 7, 24, and 63 securities licenses and earned a Bachelor of Arts degree in Economics from the University of Texas at Austin.